-

New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer

Research from Repertoire’s DECODE Platform Provides Detailed Characterization of the Immune Synapse Response in HPV 16 and HPV 33 Positive Oropharyngeal Squamous Cell Carcinoma Including Epitopes Driving Cytotoxic Response

Data to be presented at the Society for Immunotherapy of Cancer 37TH Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire® Immune Medicines will present data from its ongoing research to characterize the cellular response and identify novel therapeutic targets with the company’s DECODE™ platform in human papillomavirus (HPV) 16 and HPV 33 positive tumors. This research will be presented at the Society for Immunotherapy of Cancer (SITC 2022) 37th Annual Meeting, November 8-12, in Boston, Massachusetts.

Repertoire’s DECODE platform is a suite of integrated experimental and computational technologies designed to decipher the immune synapse, the complex interface between T cells and the epitopes they recognize, which are presented on antigen-presenting cells (APC). DECODE is being used to assess the immunogenic profile of HPV 16 and HPV 33 positive tumors in oropharyngeal squamous cell carcinoma. By characterizing the cellular response to these cancers, it is possible to identify the T cell receptors (TCR) and the specific epitopes they recognize that may be ideal targets for immunotherapies.

The company will also present data from early research in delivering interleukin-2 (IL-2) to solid tumors at efficacious levels and with reduced toxicity.

DECODE Discovery: Cellular Response and Antigen Discovery in HPV Positive Cancer

HPV16 E1 and E2 elicit a robust cytotoxic immune response in virally driven Oropharyngeal Squamous Cell Carcinoma
Presenting Author: Christine M. McInnis, Repertoire Immune Medicines, Cambridge, MA
Date/Time: Thursday, November 10 – Friday, November 11, 2022, 9:00 AM – 9:00 PM EST

HPV33-driven Oropharyngeal Squamous Cell Carcinomas are increasing in prevalence and are characterized by low CD8 infiltration and epitope presentation deficiencies
Presenting Author: Shilpa Bhatia, Repertoire Immune Medicines, Cambridge, MA
Date/Time: Thursday, November 10 – Friday, November 11, 2022, 9:00 AM – 9:00 PM EST

Cytokine Delivery Technology
Targeting wildtype IL-2 to CD8 T cells induces potent anti-tumor immune responses and decreases IL-2 mediated toxicity
Presenting Author: Selvi Ramasamy, Repertoire Immune Medicines, Cambridge, MA
Date/Time: Thursday, November 10 – Friday, November 11, 2022, 9:00 AM – 9:00 PM EST

About the DECODE™ Platform

The DECODE platform is a powerful discovery engine that characterizes essential elements of the immune synapse. In particular, the platform identifies T cell receptor-antigen pairs in the context of other important features of the immune synapse, such as T cell function and how antigens are presented by molecules on antigen-presenting cells, known as major human leukocyte antigen, or HLA, molecules. Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.

About Repertoire® Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease.

Our proprietary DECODE platform provides a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets that take place when diseased cells are present. This complex and intricate biological process is known as the immune synapse. We believe the ability to decode these interactions represents one of the greatest opportunities for innovation in medical science.

With our DECODE platform we can identify the specific T cell-antigen pairs that provide immune surveillance in cancer, generate memory responses to pathogens, and those that cause tissue damage in autoimmune disease.

Repertoire’s team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases.

To learn more about Repertoire, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.

Contacts

Repertoire Immune Medicines Contact:
Catherine Falcetti
cfalcetti@repertoire.com

Industry:

Repertoire Immune Medicines

Release Versions
English

Contacts

Repertoire Immune Medicines Contact:
Catherine Falcetti
cfalcetti@repertoire.com

More News From Repertoire Immune Medicines

Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire® Immune Medicines presented research today conducted with the company’s proprietary DECODE™ platform, which characterizes the cellular response to disease, identifying novel therapeutic targets in human papillomavirus (HPV) 16 and HPV 33-positive tumors. This research is part of Repertoire’s collaboration with Dana-Farber Cancer Institute to advance discovery and development of treatments for HPV-positive oropharyngeal (head and neck) cancers and wa...

Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire® Immune Medicines announced today that Torben Straight Nissen has been appointed as interim Chief Executive Officer, succeeding John Cox, who will continue with the company in an advisory role. With more than two decades of leadership experience, Straight Nissen joins the company as it shifts its resources and operations to focus primarily on unlocking the potential of Repertoire’s DECODE™ Platform to develop transformative immune medicines against...

Repertoire® Immune Medicines Enters New Research Collaboration to Discover the T Cell Response to Therapy in HPV-Associated Cancers

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire Immune Medicines today announced its research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to identify the immune system’s response at various stages of human papillomavirus-positive (HPV+) cancer, including initial oncogenesis and after successful treatment. The research collaboration aims to identify the antigens present on tumors as well as the T cells and specific T cell receptors (TCRs) that recognize tumor-specific antigens....
Back to Newsroom